Effects of cilostazol on angiographic restenosis after coronary stent placement

American Journal of Cardiology

Volumn 86, Issue 5, 2000, Pages 499-503

  Park, Seong Wook ^a   Lee, Cheol Whan ^a   Kim, Hyun Sook ^a   Lee, Nae Hee ^a   Nah, Deuk Young ^a   Hong, Myeong Ki ^a   Kim, Jae Joong ^a   Park, Seung Jung ^a  

^a University of Ulsan   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; CILOSTAZOL; GRANULOCYTE COLONY STIMULATING FACTOR; PHOSPHODIESTERASE INHIBITOR; TICLOPIDINE;

ADULT; AGED; ANGIOCARDIOGRAPHY; ARTICLE; BRAIN HEMORRHAGE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CORONARY ARTERY DISEASE; CORONARY STENT; DRUG INDUCED DISEASE; FEMALE; FOLLOW UP; GASTROINTESTINAL TOXICITY; HUMAN; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RASH; RESTENOSIS; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT OUTCOME;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ASPIRIN; CORONARY ANGIOGRAPHY; CORONARY DISEASE; DISEASE-FREE SURVIVAL; DRUG THERAPY, COMBINATION; FOLLOW-UP STUDIES; HUMANS; PHOSPHODIESTERASE INHIBITORS; PLATELET AGGREGATION INHIBITORS; RECURRENCE; STENTS; TETRAZOLES; TICLOPIDINE;

EID: 0342955606     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(00)01001-8     Document Type: Article

References (19)

1. Tanaka T., Ishikawa T., Hagiwara M., Onoda K., Itoh H., Hidaka H. Effects of cilostazol, a selective cAMP phosphodiesterase inhibitor, on the contraction of vascular smooth muscle. Pharmacology. 36:1988;313-320.
2. Kunishima T., Musha H., Eto F., Iwasaki T., Nagashima J., Masui Y., So T., Nakamura T. A randomized trial of aspirin versus cilostazol therapy after successful coronary stent implantation. Clin Therapeut. 19:1997;1058-1066.
3. Ochiai M., Isshiki T., Takeshita S., Eto K., Toyoizumi H., Sato T., Miyashita H. Use of cilostazol, a novel antiplatelet agent, in a post-Palmaz-Schatz stenting regimen. Am J Cardiol. 79:1997;1471-1474.
4. Dawson D.L., Cutler R.S., Meissner M.H., Strandner E. Cilostazol has beneficial effects in treatment of intermittent claudication ;Results from a multicenter, randomized, prospective, double-blind trial. Circulation. 98:1998;678-686.
5. Ikeda Y., Kikuchi M., Murakami H. Comparison of the inhibitory effects of cilostazol, acetylsalicylic acid and ticlopidine on platelet function ex vivo randomized, double blind cross-over study. Drug Research. 37:1987;563-566.
6. Take S., Matsutani M., Ueda H., Hamaguchi H., Konishi H., Baba Y., Kawaratani H., Sugiura T., Iwasaka T., Inada M. Effect of cilostazol in preventing restenosis after percutaneous transluminal coronary angioplasty. Am J Cardiol. 79:1997;1097-1099.
7. Yoshitomi Y., Kojima T., Yano M., Matsumoto Y., Kuramochi M. Antiplatelet treatment with cilostazol after stent implantation. Heart. 80:1998;393-396.
8. Park S.W., Lee C.W., Kim H.S., Lee H.J., Park H.K., Hong M.K., Kim J.J., Park S.J. Comparison of cilostazol versus ticlopidine therapy after stent implantation. Am J Cardiol. 84:1999;511-514.
9. Takahashi S., Oida K., Fujiwara R., Maeda H., Hayashi S., Takai H., Tamai T., Nakai T., Miyabo S. Effect of cilostazol, a cyclic AMP phosphodiesterase inhibitor, on the proliferation of rat aortic smooth muscle cell in culture. J Cardiovasc Pharmacol. 20:1992;900-906.
10. Kubota Y., Kichikawa K., Uchida H., Maeda M., Nishimine K., Makutani S., Sakaguchi S., Yoshioka T., Ohishi H., Kimura Y. Pharmacologic treatment of intimal hyperplasia after metallic stent placement in the peripheral arteries. Investigat Radiol. 30:1995;532-537.
11. Tsuchikane E., Fukuhara A., Kobayashi T., Kirino M., Yamasaki K., Kobayashi T., Izumi M., Otsuji S., Tateyama H., Sakurai M., Awata N. Impact of cilostazol on restenosis after percutaneous coronary balloon angioplasty. Circulation. 100:1999;21-26.
12. Morishita R., Nakamura S., Nakamura Y., Aoki M., Moriguchi A., Kida I., Yo Y., Matsumoto K., Nakamura T., Higaki J., Ogihara T. Potent role of an endothelium-specific growth factor, hepatocyte growth factor, on endothelial damage. Diabetes. 46:1997;138-142.
13. Yamasaki M., Yuji I., Kobayashi N., Kozuma K., Ohmoto Y., Oh-Hashi Y., Ako J., Nakajima H., Chiku N., Saeki F., Tamura T. Effects of cilostazol on late lumen loss after Palmaz-Schatz stent implantation. Cathet Cardiovasc Diagn. 44:1998;387-391.
14. Kunishima T., Musha H., Eto F., Iwaski T., Nagashima J., Masui Y., So T., Nakamura T., Oohama N., Murayama M. A randomized trial of aspirin versus cilostazol therapy after successful coronary stent implantation. Clin Therapeut. 19:1997;1058-1066.
15. Mehran R., Dangas G., Abizaid A.S., Mintz G.S., Lansky A.J., Satler L.F., Pichard A.D., Kent K.M., Stone G.W., Leon M.B. Angiographic patterns of in-stent restenosis classification and implications for the long-term outcome. Circulation. 100:1999;1872-1878.
16. Brack M.J., Hubner P.J., Gershlick A.H. Anticoagulation after intracoronary stent insertion. Br Heart J. 72:1994;294-296.
17. Schoemig A., Neumann F.J., Kastrati A., Schuhlen H., Blasini R., Hadamitzky M., Walter H., Zitzmann-Roth E.M., Richardt G., Alt E., Schmitt C., Ulm K. A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. N Engl J Med. 334:1996;1084-1089.
18. Goods C.M., al-Shaibi K.F., Liu M.W., Yadav J.S., Mathur A., Jain S.P., Dean L.S., Iyer S.S., Park J.M., Roubin G.S. Comparison of aspirin alone versus aspirin plus ticlopidine after coronary artery stenting. Am J Cardiol. 78:1996;1042-1044.
19. Yasunaga K., Mase K. Antiaggregatory effect of oral cilostazol and recovery of platelet aggregability in patients with cerebrovascular disease. Arzneimittelforschung/Drug Res. 35:1985;1189-1192.